Medical Devices APAC

APAC Point-of-Care Molecular Diagnostics Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Point-of-Care Molecular Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Technology, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $795.5 Mn Placeholder estimate
Estimate 2025 $887.8 Mn 22.9% of the global market
Projected 2034 $2.38 Bn 168.5% Adds $1.50 Bn over 9 forecast years
CAGR 2025–2034 11.6% Faster than 65% of 180 Medical Devices markets here
Key players 5
  • APAC is 22.93% of the global market.
  • Among regions, the largest is North America at $1.75 Bn.
  • Fastest growing: APAC (this report) at 11.6% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.50 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Point-of-Care Molecular Diagnostics Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $795.5 Mn — —
2025 (base) $887.8 Mn +$92.3 Mn —
2026 (forecast) $990.7 Mn +$103.0 Mn +11.6%
2027 (forecast) $1.11 Bn +$114.9 Mn +24.5%
2028 (forecast) $1.23 Bn +$128.3 Mn +39%
2029 (forecast) $1.38 Bn +$143.1 Mn +55.1%
2030 (forecast) $1.54 Bn +$159.7 Mn +73.1%
2031 (forecast) $1.72 Bn +$178.3 Mn +93.2%
2032 (forecast) $1.91 Bn +$198.9 Mn +115.6%
2033 (forecast) $2.14 Bn +$222.0 Mn +140.6%
2034 (forecast) $2.38 Bn +$247.8 Mn +168.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Point-of-Care Molecular Diagnostics Market Analysis at a glance
Market size, 2025$887.8 Mn placeholder estimate
Forecast, 2034$2.38 Bn placeholder estimate
Growth (CAGR), 2025–203411.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, technology and end user (see all)
Key playersCepheid, Abbott Laboratories, Roche Diagnostics, bioMérieux SA, Visby Medical (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Point-of-Care Molecular Diagnostics Market Analysis Executive Summary

Point-of-care molecular diagnostics run PCR and similar DNA tests near the patient, giving lab-quality results in minutes.

Key segments of the point-of-Care Molecular Diagnostics market include test (Respiratory Infections, Sexually Transmitted Infections and Hospital Infections) and technology (PCR and Isothermal Amplification).

Bar chart: Asia Pacific Point-of-Care Molecular Diagnostics market size, 2024–2034, placeholder estimates. $795.5 Mn in 2024, $887.8 Mn in 2025 and $2.38 Bn in 2034, 11.6% CAGR.
Asia Pacific Point-of-Care Molecular Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Point-of-Care Molecular Diagnostics Market Dynamics

Market Growth Drivers

Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the point-of-Care Molecular Diagnostics market.

Opportunity

Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the point-of-Care Molecular Diagnostics market room to grow, especially in emerging markets.

Market Restraints

Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the point-of-Care Molecular Diagnostics market.

Competitive Landscape for Point-of-Care Molecular Diagnostics Market in APAC

The point-of-Care Molecular Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Point-of-Care Molecular Diagnostics Market in APAC

Point-of-Care Molecular Diagnostics in APAC: rules and payment

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9], Thai FDA (Thailand)⁠[10], Ministry of Health (Indonesia)⁠[11], DRAP (Pakistan)⁠[12], MFDS (South Korea)⁠[13] and Ministry of Health (Vietnam)⁠[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[15], basic medical insurance (China)⁠[16], the Hospital Authority (Hong Kong)⁠[17], Ayushman Bharat PM-JAY (India)⁠[18], public health insurance (Japan)⁠[19], subsidised public care (Malaysia)⁠[20], Pharmac (New Zealand)⁠[21], PhilHealth (Philippines)⁠[22], MediShield Life (Singapore)⁠[23], the Universal Coverage Scheme (Thailand)⁠[24], JKN (BPJS Kesehatan) (Indonesia)⁠[25], out of pocket and Sehat Sahulat (Pakistan)⁠[26], National Health Insurance (South Korea)⁠[27] and social health insurance (Vietnam)⁠[28].

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Ministry of Health of Indonesia. Checked 19 Nov 2026.

[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.

[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.

[14] Ministry of Health of Vietnam. Checked 19 Nov 2026.

[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[16] National Healthcare Security Administration. Checked 14 Nov 2026.

[17] Hospital Authority. Checked 14 Nov 2026.

[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[20] Ministry of Health Malaysia. Checked 14 Nov 2026.

[21] Pharmac. Checked 14 Nov 2026.

[22] PhilHealth. Checked 14 Nov 2026.

[23] CPF Board, MediShield Life. Checked 14 Nov 2026.

[24] National Health Security Office. Checked 14 Nov 2026.

[25] BPJS Kesehatan. Checked 19 Nov 2026.

[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[28] Vietnam Social Security. Checked 19 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how point-of-Care Molecular Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Point-of-Care Molecular Diagnostics right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Point-of-Care Molecular Diagnostics in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Point-of-Care Molecular Diagnostics market in Asia Pacific?
Placeholder estimate: about $887.8 Mn in 2025, rising to about $2.38 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Point-of-Care Molecular Diagnostics market in Asia Pacific growing?
Placeholder estimate: about 11.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Point-of-Care Molecular Diagnostics market report cover?
The report splits the market by test (Respiratory Infections, Sexually Transmitted Infections, Hospital Infections, Oncology), technology (PCR, Isothermal Amplification) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Point-of-Care Molecular Diagnostics market?
Key players include Cepheid, Abbott Laboratories, Roche Diagnostics, bioMérieux SA and Visby Medical.
What is driving the Point-of-Care Molecular Diagnostics market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the point-of-Care Molecular Diagnostics market.
How much research is published on Point-of-Care Molecular Diagnostics?
PubMed lists 43 papers on Point-of-Care Molecular Diagnostics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in APAC

See all

Related on diagnostics and lab testing

See the topic